Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor. In this report, we show that modulation of s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Grohar, Patrick J, Griffin, Laurie B, Yeung, Choh, Chen, Qing-Rong, Pommier, Yves, Khanna, Chand, Khan, Javed, Helman, Lee J
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press Inc. 2011
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033593/
https://ncbi.nlm.nih.gov/pubmed/21403840
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars